* Treatment of MS patients in Sweden started as part of the SAIK-MS Phase II clinical study
* TTS Phase II cancer studies proceeding as planned - renal cancer patients now receiving treatment, inclusion of pancreatic cancer patients under way
* European registration application for Dukoral submitted by PowderJect Pharmaceuticals - possibility of receiving additional milestone payments
* Collaboration discussions ongoing with international pharmaceutical companies
* Loss after net financial items of SEK 63.9 million (-SEK 86.6 m) - an improvement attributable to the focus on core operations
